Potential for peroxisome proliferator-activated receptor-γ agonists in progression: Beyond metabolism

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 3, 2008, Pages 282-285

  Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin; Peroxisome proliferator activated receptor agonist; Podocytes; Sclerosis; Transforming growth factor

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE;

AGONIST; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG MECHANISM; HUMAN; HYPERLIPIDEMIA; KIDNEY INJURY; MESANGIUM CELL; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; PODOCYTE; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; PPAR GAMMA; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA;

EID: 42149086477     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f9b1c0     Document Type: Review

References (25)

1. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006; 70:1223-1233.
2. Tontonoz P, Nagy L, Alvarez JG, et al. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93:241-252.
3. Ma LJ, Marcantoni C, Linton MF, et al. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001; 59:1899-1910.
4. Yoshida K, Kohzuki M, Xu HL, et al. Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure. J Hypertens 2001; 19:503-510.
5. Yang HC, Ma LJ, Ma J, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 2006; 69:1756-1764.
6. Paueksakon P, Revelo MP, Ma LJ, et al. Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int 2002; 61:2142-2148.
7. Revelo MP, Federspiel C, Helderman H, Fogo AB. Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma. Nephrol Dial Transplant 2005; 20:2812-2819.
8. Kanjanabuch T, Ma LJ, Chen J, et al. PPAR-gamma agonist protects podocytes from injury. Kidney Int 2007; 71:1232-1239. The beneficial effect of PPARγ agonists on podocyte injury in vitro is shown.
9. Okada T, Wada J, Hida K, et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes 2006; 55:1666-1677.
10. Ma LJ, Jha S, Ling H, et al. Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 2004; 65:106-115.
11. Benigni A, Zoja C, Corna D, et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003; 14:1816-1824.
12. Ohga S, Shikata K, Yozai K, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol 2007; 292:F1141-F1150. This article provides evidence for the beneficial effects of PPARγ agonists in decreasing inflammation and inhibiting nuclear factor κB in diabetic injury.
13. Ohtomo S, Izuhara Y, Takizawa S, et al. Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int 2007; 72:1512-1519. This study provides evidence to support the actions of PPARγ agonists beyond glycemic control in vivo.
14. Maeda A, Horikoshi S, Gohda T, et al. Pioglitazone attenuates TGF-beta(1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)gamma. Cell Biol Int 2005; 29:422-428.
15. Nicholas SB, Kawano Y, Wakino S, et al. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension 2001; 37:722-727.
16. Zafiriou S, Stanners SR, Saad S, et al. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol 2005; 16:638-645.
17. Li Y, Wen X, Spataro BC, et al. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 2006; 17:54-65.
18. Erbe DV, Gartrell K, Zhang YL, et al. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 2006; 45:154-162.
19. Suganuma E, Babaev V, Fogo A, et al. Macrophages deficient in peroxisome proliferators-activated receptor-γ accelerate angiotensin II-induced atherosclerosis [abstract]. J Am Soc Nephrol 2004; 15:5A.
20. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471.
21. Doggrell SA. Does rosiglitazone increase cardiovascular outcomes? Expert Opin Pharmacother 2007; 8:2665-2669.
22. Hanefeld M. Is rosiglitazone associated with increased risk for cardiovascular events? Nat Clin Pract Cardiovasc Med 2007; 4:648-649.
23. Jin HM, Pan Y. Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. Kidney Blood Press Res 2007; 30:203-211. Improved renal function with lower serum creatinine and proteinuria was observed in patients with diabetes with a combination of ARB and PPARγ agonist, linked to improved glycemic control.
24. Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53:336-346.
25. Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007; 72:1367-1373. These authors makes important observations in humans with diabetes of improved renal function linked to PPARγ agonists, independent of glycemic effects, possibly mediated by effects on tumor necrosis factor-α and adiponectin.